Pricing

Cheapest Microdose Tirzepatide: Prices, and What the Dose Actually Is (2026)

Microdose programmes run $110 to $349 a month, with NexLife (opens nexlife.us in a new tab)'s captured at $147 on twelve months and $189 month-to-month. They deliver roughly 1 mg weekly against the 5, 1

Read this before the price table

A microdose programme is not a discount tier of a standard programme. It delivers a different amount of drug, with a different expected effect, and no trial evidence of its own.

SURMOUNT-1 reported mean weight reduction of about 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg over 72 weeks, against 3.1% with placebo. The relationship is clean: more dose, more effect.

A roughly 1 mg weekly dose sits below every dose tested. Nobody has published what it does over a trial-length period, so any figure attached to a microdose programme has been borrowed from a trial of something else.

The prices

Captured by us: NexLife (opens nexlife.us in a new tab) at $147 a month on a twelve-month plan and $189 month-to-month, flat at every covered dose, no membership fee, read from its own plan pages on 11 July 2026.

Provider-reported: Enhance.MD at $169 for a stated 1 mg weekly programme including lab testing, delivered twelve-weekly. Shed at $199 with a two-month minimum. Gala for microdosing. bmiMD at $349, which is above most competitors' standard injectable pricing.

Compounded semaglutide microdose programmes start lower, at $110 a month.

What the saving actually is

Within the same provider, a microdose typically saves $30 to $110 a month against the standard programme. NexLife (opens nexlife.us in a new tab): $147 against $186. Enhance.MD: $169 against $280. Shed: $199 against $245. bmiMD is the outlier at $349 against $399.

So the question is not whether it is cheaper. It is whether the lower dose does what you need — a clinical question with no published answer at that dose.

The comparison that reframes it

The cheapest FDA-approved GLP-1 of any kind is $149 a month at its starting dose, with published trial data, FDA review and manufacturer supply. Two microdose programmes in our dataset cost more than that.

Eligible Medicare enrollees pay $50 through the GLP-1 Bridge, and a covered brand can land near $25. Both are below every microdose programme here, for an approved product at a studied dose.

Why the category exists

Partly clinical and partly regulatory, and it is worth separating the two.

Clinically, prescribers reduce doses for real reasons: side-effect burden, comorbidities, patient preference, or maintenance after a period at a full dose. A patient who cannot tolerate 10 mg is better served at 5 than at nothing, and the label's titration is explicitly tolerability-driven.

Regulatorily, compounding a copy of an available approved product is generally not permitted. Compounding something a prescriber documents as clinically different for an individual patient is. That documentation requirement is what “personalised dosing” satisfies.

This explains the timing better than any clinical development does: the microdose category expanded when the shortage listings ended, not when new evidence appeared.

The maintenance argument, examined

The strongest case for low-dose therapy is maintenance — someone who reached a target on a full dose, then reduces to hold it. That is a recognised pattern in other chronic conditions.

The gap is that it has not been tested here. SURMOUNT-4 studied continuation at maximum tolerated dose against complete withdrawal. It did not study reduction to a low dose, which is the intermediate option the maintenance argument depends on.

A provider offering microdosing as maintenance is therefore extrapolating from a trial that tested something else. That may still be sound clinical judgement for an individual patient — but it is judgement, not evidence, and it should be described that way.

Four questions before enrolling

1. What weekly dose does this deliver, in milligrams? A programme that will not answer cannot be compared with anything, including itself over time.
2. What evidence exists for that dose specifically?
3. Is the plan to escalate, and does the price change if I do?
4. If this is maintenance dosing, what was I meant to have done first?

Questions readers actually ask

Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.